Stay updated on Selinexor Maintenance in p53 Wild-Type Endometrial Carcinoma Clinical Trial
Sign up to get notified when there's something new on the Selinexor Maintenance in p53 Wild-Type Endometrial Carcinoma Clinical Trial page.

Latest updates to the Selinexor Maintenance in p53 Wild-Type Endometrial Carcinoma Clinical Trial page
- Check3 days agoChange DetectedThe recruitment status was updated to Active, not recruiting; enrollment and site counts were revised (276 estimated to 257 actual; 217 locations to 204), and the page version was bumped to v3.5.5.SummaryDifference15%

- Check10 days agoNo Change Detected
- Check17 days agoNo Change Detected
- Check24 days agoChange DetectedThe study page was updated to Revision: v3.5.4, representing an internal update to the page's revision history. It does not modify any study details, endpoints, or inclusion criteria visible to users.SummaryDifference0.0%

- Check31 days agoChange DetectedThe Taiwan site listing was updated from 'Taoyuan, Taiwan, 333' to 'Taoyuan City, Taiwan, 333' to clarify the precise city designation. This clarifies the recruitment location for that site within the study's geographic footprint.SummaryDifference0.0%

- Check39 days agoChange DetectedThe page footer's Revision tag has been updated from v3.5.2 to v3.5.3, representing a new build of the page without changes to the underlying study details.SummaryDifference0.0%

- Check46 days agoChange DetectedUpdated study record dates/status entries (e.g., listing newer posted/last update timestamps and a withdrawn indicator). Removed an earlier named investigator/contact and associated role/contact/location status information.SummaryDifference0.1%

- Check53 days agoChange Detected- The page metadata now shows Revision: v3.5.2; the previous label v3.5.0 has been removed.SummaryDifference0.0%

Stay in the know with updates to Selinexor Maintenance in p53 Wild-Type Endometrial Carcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Selinexor Maintenance in p53 Wild-Type Endometrial Carcinoma Clinical Trial page.